Enanta Pharmaceuticals at IDWeek 2026

Oct 21–24, 2026 Washington, DC ~12k attendees Website

Enanta Pharmaceuticals brings 1 presentation to IDWeek 2026 in Washington, and exhibits at Booth BS 29. Its program centres on zelicapavir, its RSV antiviral, in high-risk adults. Its randomized, placebo-controlled trial reports shorter time to full symptom resolution and reductions in hospitalization and viral load.

OrganizationIDWeek 2026 Attendance
enanta.com
Biotech
Clinical-stage biotech making oral antiviral and immunology drugs, now focused on RSV; it co-discovered two hepatitis C protease inhibitors sold by AbbVie.
Booth
Exhibiting at Booth BS 29
Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm
Poster
Thu Oct 22
12:15pm–1:30pm
Zelicapavir Decreases Time to Complete RSV Symptom Resolution, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo (PBO)-Controlled Phase 2 Trial of High-Risk Adults
Poster Hall B-C · Poster P-3
A1. Novel Agents

Explore the full IDWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Washington. Leave your work email and we’ll be in touch.

Privacy

Download the full IDWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Enanta Pharmaceuticals

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction